Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.

about

Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".Disease activity following pregnancy-related discontinuation of natalizumab in MS.

P2860

Q49484199-5AD91D6E-34CF-4A34-A4BA-84A7D1EFACCB Q49590553-466F3CEE-0F8A-486D-BC5B-CF680DD6E9FF

P2860

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.

Item

http://www.wikidata.org/entity/Q38842554

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Population Pharmacokinetics an ...... ients With Multiple Sclerosis.

@en

type

Item

label

Population Pharmacokinetics an ...... ients With Multiple Sclerosis.

@en

prefLabel

Population Pharmacokinetics an ...... ients With Multiple Sclerosis.

@en

P1476

Population Pharmacokinetics an ...... ients With Multiple Sclerosis.

@en

P2093

Daniel D Mikol

http://www.w3.org/2001/XMLSchema#string

Geoffrey Kuesters

http://www.w3.org/2001/XMLSchema#string

Ivan Nestorov

http://www.w3.org/2001/XMLSchema#string

Kumar Kandadi Muralidharan

http://www.w3.org/2001/XMLSchema#string

Meena Subramanyam

http://www.w3.org/2001/XMLSchema#string

Sreeja Gopal

http://www.w3.org/2001/XMLSchema#string

Tatiana Plavina

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Lymphatic transport of proteins after subcutaneous administration.

Natalizumab in the treatment of multiple sclerosis

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.

P304

1017-1030

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.894

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28398628

http://www.w3.org/2001/XMLSchema#string

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.

about

P2860

P2860

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698